[1] van den EYNDE J,SÁ MPBO,VERVOORT D,et al.Pulmonary valve replacement in tetralogy of fallot:An updated meta-analysis[J].Ann Thorac Surg,2022,113(3):1036-1046. [2] YOKOYAMA Y,KUNO T,TOYODA N,et al.Ross procedure versus mechanical versus bioprosthetic aortic valve replacement:A network meta-analysis[J].J Am Heart Assoc,2023,12(1):e8066. [3] SWIFT S L,PUEHLER T,MISSO K,et al.Transcatheter aortic valve implantation versus surgical aortic valve replacement in patients with severe aortic stenosis:A systematic review and meta-analysis[J].BMJ Open,2021,11(12):e054222. [4] FU G,ZHOU Z,HUANG S,et al.Mitral valve surgery in patients with rheumatic heart disease:Repair vs.replacement[J].Front Cardiovasc Med,2021(8):685746. [5] TRONGTORSAK A,THANGJUI S,ADHIKARI P,et al.Gender disparities after transcatheter aortic valve replacement with newer generation transcatheter heart valves:A systematic review and meta-analysis[J].Med Sci,2023,11(2):33. [6] YASMIN F,JAWED S,NAJEEB H,et al.Comparative efficacy and safety of mitral valve repair versus mitral valve replacement in Rheumatic heart disease:A high-value care systematic review and meta-analysis[J].Curr Probl Cardiol,2024,49(6):102530. [7] 王霞,刘延丽.围术期护理对心脏瓣膜置换术中自体血回输患者血气指标,凝血功能及输血并发症的影响[J].血栓与止血学,2022,28(3):707-708,710. [8] 姬金兰,李秋菊,李佳弟,等.风湿性心脏病患者心脏瓣膜置换术中体温对心脏复跳及心肌损伤的影响[J].中国卫生检验杂志,2023,33(8):954-957. [9] 刘罗,张艳,李春莉,等.经导管主动脉瓣置换术后心脏传导阻滞发生与影响因素分析[J].昆明理工大学学报(自然科学版),2022,47(4):97-102. [10] 朱天翔,李淑娴,陈天博,等."全程管理模式"在心脏瓣膜置换术后患者抗凝治疗中的应用观察[J].山东医药,2022,62(6):21-24. [11] VERSTRAETE A,HERREGODS M C,VERBRUGGHE P,et al.Antithrombotic treatment after surgical and transcatheter heart valve repair and replacement[J].Front Cardiovasc Med,2021(8):702780. [12] 施熠婷,郭琳琳,查桂珍,等.双心模式干预对风湿性心脏病瓣膜置换术患者预后的影响[J].海军医学杂志,2022,43(4):395-399. [13] 赵慧明,刘勇,粟丽,等.ORBIT评分与HAS-BLED评分对心脏瓣膜置换术后华法林抗凝出血风险的预测价值比较[J].实用临床医药杂志,2024,28(6):83-87. [14] 周庆秋,杜永丽,冯飞飞,等.临床药师参与1例心脏瓣膜置换术后肿瘤合并脑出血患者的抗凝治疗实践[J].中国医药科学,2023,13(14):187-190. [15] 秦学伟,陈宣伶,姚兰,等.小剂量重组活化人凝血因子Ⅶ对再次心脏多瓣膜置换术患者凝血功能的影响[J].中国循环杂志,2023,38(9):962-967. [16] 潘华英,罗玲玲,杨梦娇,等.心脏机械瓣膜置换术后华法林抗凝治疗出血并发症的研究进展[J].全科护理,2022,20(2):191-195. [17] 洪珊珊,严美华,傅新阳,等.心脏瓣膜置换术后服用华法林致出血的危险因素分析[J].中外医疗,2022,41(35):54-58. [18] 陈敏,吴艳琳,雷立华.氨甲环酸对心脏瓣膜置换术围术期出血和血液保护的回顾性研究[J].福建医药杂志,2022,44(5):41-44. [19] 李晓烨,许青,李晓宇,等.药物相关基因型指导的华法林初始给药剂量对心脏瓣膜置换术后抗凝疗效的影响[J].上海医药,2022,43(5):1-3,31. [20] 王秋珍. 标准化随访流程对心脏机械瓣膜置换术后患者抗凝治疗认知状况的改善效果[J].吉林医学,2022,43(12):3420-3422. [21] 雷远丽,倪云潮,陈寿权,等.急诊科华法林相关致命性出血114例分析[J].中华急诊医学杂志,2021,30(3):336-341. [22] 张欢,杨桂玲,高义玲,等.心脏瓣膜置换术后发生心包积液抗凝治疗的研究[J].中国医药导刊,2021,23(5):321-324. [23] 喻君,金孝岠,郭建荣,等.不同时机应用氨甲环酸对体外循环心脏瓣膜手术患者凝血功能及出血量的影响[J].中国临床药理学与治疗学,2019,24(12):1415-1420. [24] 沈蒙蒙,季明雪,赵文超.老年患者体外循环下心脏术后发生急性呼吸窘迫综合征的危险因素分析[J].中国循证心血管医学杂志,2024,16(7):860-862. [25] 王宝彦,严思敏,许婉婷,等.心脏机械瓣膜置换术后抗凝治疗中消化道出血的研究[J].药学服务与研究,2020,20(4):247-250. |